UBS Group’s Impact BioMedical IBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.67K Buy
299
+109
+57% +$638 ﹤0.01% 10195
2026
Q2
$1.1K Sell
190
-2,379
-93% -$17.8K ﹤0.01% 9627
2026
Q1
$19.4K Buy
2,569
+2,397
+1,394% +$15.1K ﹤0.01% 7952
2025
Q4
$1.1K Sell
172
-1,420
-89% -$9.48K ﹤0.01% 9705
2025
Q3
$13.4K Sell
1,592
-1,556
-49% -$12.4K ﹤0.01% 8401
2025
Q2
$25.7K Buy
3,148
+1,867
+146% +$13.2K ﹤0.01% 8282
2025
Q1
$14.1K Buy
1,281
+944
+280% +$20.6K ﹤0.01% 8444
2024
Q4
$6.16K Buy
+337
New +$8.82K ﹤0.01% 8588
2024
Q3
– Hold
0
– – – 9381

Other funds holding IBO

UBS Group's IBO Position: Q3 2026 in Review

UBS Group increased its Impact BioMedical (IBO) stake by 57% in Q3 2026, buying an estimated $638 and bringing the position to 299 shares worth $1.67K. The position accounts for ﹤0.01% of the portfolio, ranked #10195.

UBS Group first reported a position in IBO in Q4 2024 and has held it in 8 quarters since. The position peaked at $25.7K in Q2 2025. 19 funds tracked by Wall St. Rank hold IBO as of Q3 2026.

  • UBS Group held 299 shares of Impact BioMedical worth $1.67K as of Q3 2026.
  • UBS Group bought 109 Impact BioMedical shares in Q3 2026, an estimated $638.
  • Impact BioMedical made up ﹤0.01% of UBS Group's portfolio in Q3 2026, its #10195 holding.
  • UBS Group first reported a position in Impact BioMedical in Q4 2024 and has held it in 8 quarters since.
  • UBS Group's Impact BioMedical position peaked at $25.7K in Q2 2025.
  • 19 funds tracked by Wall St. Rank held Impact BioMedical as of Q3 2026.

Based on UBS Group's 13F filing for Q3 2026, filed 10 Nov 2026.